Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.

ABSTRACT:

Background

Resistance to isoniazid is the most common form of drug-resistance in tuberculosis. However only a tiny proportion of TB patients in the world have access to isoniazid drug susceptibility testing-the widely implemented Xpert MTB/RIF technology only tests for resistance to rifampicin. Patients with isoniazid mono resistance that is not identified at baseline are treated with a standard regimen that effectively results in rifampicin mono-therapy during the latter four months of the six month treatment course, exposing remaining viable organisms to a single agent and greatly increasing the risk of development of multi drug-resistant TB. Unusually, Peru has pioneered universal pre-treatment drug susceptibility testing with methods that identify isoniazid resistance and has t

SUBMITTER: Cornejo Garcia JG 

PROVIDER: S-EPMC6279036 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature